ARID2 and glioblastoma: Additionally, there were likely oncogenic truncating mutations recurrently affecting genes involved in histone tail methylation (SETD2: 6/9, 67%), histone tail acetylation (EP300 or CREBBP: 3/9, 33%), chromatin remodeling (ARID2 or ARID5B: 5/9, 56%), or BCL6-associated transcriptional co-repression (BCOR or BCORL1: 3/9, 33%) enriched in the de novo RRD glioblastomas compared to the conventional glioblastoma cohort.